share_log

海思科:创新药HSK21542注射液新适应症IND申请获受理

Securities Times ·  Jul 14 04:11

e公司讯,海思科(002653)7月14日晚间公告,子公司创新药HSK21542注射液拟用于治疗术后恶心呕吐的境内生产药品注册临床试验申请获国家药监局受理。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment